



*From Nature for Life*

## PRESS RELEASE

### **Admission of all offer conditions - Grifols S.A. acquires majority of voting rights in Biotest AG**

- Turkish Competition Authority grants approval
- Completion of the takeover bid as of 25 April 2022

*Dreieich, 12 April 2022.* Grifols S.A. announces today that the last outstanding offer condition mentioned in the offer document, the clearance of the overall transaction by the competition authorities in Turkey, has occurred on 7 April 2022. The Turkish Competition Authority (Rekabet Kurumu Başkanlığı) has announced that the proposed merger has been approved. Thus, all offer conditions have been fulfilled. The overall transaction is therefore no longer subject to a closing prohibition.

The takeover bid published on 26 October 2021 can be completed. Following the closing, Grifols S.A. will hold 96.2% of the ordinary shares and 43.2% of the preference shares as of today's date.

Grifols S.A. has notified that the payment of the offer price in the amount of €43.00 per tendered ordinary share and €37.00 per tendered preference share will be made no later than 25 April 2022.

#### About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,000 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

#### **IR contact**

Dr Monika Buttker  
Phone: +49-6103-801-4406  
Mail: [ir@biotest.com](mailto:ir@biotest.com)

#### **PR contact**

Dirk Neumüller  
Phone: +49-6103-801-269  
Mail: [pr@biotest.com](mailto:pr@biotest.com)

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, [www.biotest.com](http://www.biotest.com)

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201

Preference shares: securities' ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.